Pfizer's PFE stock has risen 5% since it reported first-quarter results on April 29. While the company beat estimates for ...

Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

With its stock down 7.6% over the past three months, it is easy to disregard Pfizer (NYSE:PFE). We, however decided ...

Pfizer Inc. has been recognized as a leading dividend stock, attracting attention from investors after recent insider buying ...

Pfizer's robust product pipeline and consistent R&D investments position it well for future growth. See why I rate PFE stock ...

The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...

Pfizer said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research ...

For years, Pfizer was the only drugmaker with treatments for the disease, called ATTR-CM, but BridgeBio’s CEO said in an ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research ...

Pfizer has reported positive results from a Phase III trial of sasanlimab and Bacillus Calmette-Guérin (BCG) for treating ...